Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Language: search.filters.language.EnglishSubject: search.filters.subject.biomarker

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Serum amyloid A as a biomarker: diagnostic relevance and clinical association with acute ischemic stroke
    (MEDICAL FACULTY - SKOPJE, 2025-10-16)
    Ivanovska, Slavjana
    ;
    ;
    ;
    Kerala, Coskun
    ;
    Kostovska, Irena
    Serum amyloid A (SAA) is an acute-phase protein that circulates at low levels bound to high-density lipoproteins (HDL). During inflammation, its concentration rises sharply, altering HDL composition, lipid transport, and cholesterol metabolism. These changes contribute to vascular pathology, particularly atherosclerosis. Owing to its multifunctional role, SAA has gained attention as a potential biomarker in cardiovascular and cerebrovascular diseases, although its role in acute ischemic stroke (AIS) remains insufficiently clarified.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine
    (MDPI AG, 2022-12-16)
    ;
    Rusevski, Aleksandar
    ;
    ;
    Popov, Zivko
    ;
    <jats:p>As the currently available tests for the clinical management of prostate cancer (PCa) are still far from providing precise diagnosis and risk stratification, the identification of new molecular marker(s) remains a pertinent clinical need. Candidate PCa biomarkers from the published proteomic comparative studies of prostate tissue (2002–2020) were collected and systematically evaluated. AZGP1, MDH2, FABP5, ENO1, GSTP1, GSTM2, and EZR were chosen for further evaluation in the urine of 85 PCa patients and controls using ELISA. Statistically significant differences in protein levels between PCa and BPH showed FABP5 (p = 0.019) and ENO1 (p = 0.015). A biomarker panel based on the combination of FABP5, ENO1, and PSA provided the highest accuracy (AUC = 0.795) for PCa detection. The combination of FABP5, EZR, AZGP1, and MDH2 showed AUC = 0.889 in PCa prognosis, with 85.29% of the samples correctly classified into low and high Gleason score (GS) groups. The addition of PSA to the panel slightly increased the AUC to 0.914. AZGP1, FABP5, and EZR showed significant correlation with GS, stage, and percentage of positive biopsy cores. Although validation using larger patient cohorts will be necessary to establish the credibility of the proposed biomarker panels in a clinical context, this study opens a way for the further testing of more high-quality proteomics biomarkers, which could ultimately add value to the clinical management of PCa.</jats:p>